Capecitabine

Producers shown on SFDA

(Record date:06/09/2021）

Producers shown on EP

(Quoted from EP website；record date:06/09/2021）

Producer:Lianyungang Guike Pharmaceutical Co., Ltd., established in 2006, is a high-tech integrated pharmaceutical manufacturer focuses on research, development, production and sales of pharmaceutical raw material. Located at No. 1 Xianfeng Road, Dapu Industrial Park, Lianyungang Economic and technological development zone,  and covers a total area of around 31148.9m2   with all facilities built strictly according to the GMP standard. The factory owns many internationally leading equipment imported from Europe and the United States. The products are popular for high quality and have customers in Japan, Korea, Russia, Belarus, Turkey, Pakistan, Indonesia, etc.

Staff size:50-99 persons

Registered capital:RMB 43 million 23 thousand and 566

Producer:Founded in 2005, Jiangsu Shengdi Pharmaceutical Co., Ltd. is mainly engaged in the R & D and production of pharmaceutical raw materials, formerly known as the API branch of Jiangsu Hengrui Pharmaceutical Co., Ltd.

The company is now deregistered

Staff size:/

Registered capital:RMB 50 million

Producer:Lianyungang Runzhong Pharmaceutical Co., Ltd., a wholly-owned subsidiary and API production base of Zhengda Tianqing Pharmaceutical Group, was established in 2010, covering an area of 206 mu. In 2012, it was recognized as a high-tech enterprise, mainly engaged in the R & D, production and sales of various chemical APIs.

At present, the company has 7 product production workshops, 4 pilot workshops for new products, 1 product development center, and 2 drug inspection centers, power workshops and warehouses. There are 52 products approved for listing in China, of which 16 are listed as high-tech products in Jiangsu Province, involving liver disease, tumor, cardiovascular, respiratory and other fields, with an annual production capacity of more than 100 tons.

With the continuous increase of product types and production scale, the economic benefits of the company have also increased year by year. In 2020, the sales revenue will reach 3.5 billion yuan, including 10 API products such as arotinib hydrochloride, magnesium isoglycyrrhizinate and Diammonium Glycyrrhizinate, forming a "product group with sales of more than 100 million". The company has passed FDA certification for "zero defect" twice, and 14 products passed GMP on-site inspection in 2020, indicating that the company's quality management is at a high level in the industry.

Staff size:1000-1999 persons

Registered capital:RMB 103 million 528 thousand and 805

Producer:Qilu Tianhe Huishi Pharmaceutical Co., Ltd. is a Sino foreign joint venture jointly invested and established by Qilu Pharmaceutical Co., Ltd. and anty Hong Kong International Co., Ltd. in 2006.

The company is now deregistered.

Staff size:2000-2999 persons

Registered capital:RMB 612.5 million

Producer:Jiangsu Hengrui Medicine Co.,Ltd. is a pharmaceutical company engaged in the development and commercialization of innovative and high-quality drugs. 

The company has 28000 employees globally, fifth R & D centers were built around the globe and several subsidiaries were established in the US, EU, and Japan.

The company has 10 manufacturing facilities and most of them maintain USP, EUP, and JP. We are the first Chinese company that exported injections on a large scale to the US, EU, and Japan markets. All dosage forms of the company have passed the national GMP certification, and ifosfamide, etoposide, mesilar and tiotepa have passed the verification of FDA.

Staff size:About 30000 persons

Registered capital:RMB 6 billion 397 million